“Rocket made meaningful progress during the third quarter, notably with the completion of enrollment in the RP-A501 program for Danon disease, low dose cohort enrollment completion in the RP-A601 program for PKP2-ACM, and appointment of seasoned pharmaceutical executive, Mikael Dolsten to our Board of Directors,” said Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharmaceuticals (RCKT). “As we continue to pursue our mission of seeking gene therapy cures for patients with rare and devastating diseases, we remain focused on expediently advancing our deep pipeline of cardiovascular and hematology programs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- RCKT Upcoming Earnings Report: What to Expect?
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Rocket Pharmaceuticals initiated with an Outperform at Scotiabank
- Biotech Alert: Searches spiking for these stocks today
- Rocket Pharmaceuticals: All patients enrolled in RP-A501 study to treat Danon